Cargando…
Capsule and Sprinkle Formulations of Lubiprostone Are Not Biologically Similar in Patients with Functional Constipation
INTRODUCTION: Lubiprostone capsules are approved for managing three different chronic constipation conditions. A “sprinkle” formulation may facilitate use in individuals with difficulty swallowing capsules. Our objective was to evaluate the bioequivalence, pharmacokinetics (PK), and bioavailability...
Autores principales: | Adams, Atoya, Barish, Charles, Chen, Angel, Dennis, Patrick, Krause, Richard, Lichtlen, Peter, Losch-Beridon, Taryn, Mareya, Shadreck, Schneider, Jeffrey |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8190023/ https://www.ncbi.nlm.nih.gov/pubmed/33834354 http://dx.doi.org/10.1007/s12325-021-01707-9 |
Ejemplares similares
-
Effects of baseline abdominal pain and bloating on response to lubiprostone in patients with irritable bowel syndrome with constipation
por: Chang, L., et al.
Publicado: (2016) -
Safety of Lubiprostone in Pediatric Patients With Functional Constipation: A Nonrandomized, Open-Label Trial
por: Hussain, Sunny Z., et al.
Publicado: (2021) -
The Cost Effectiveness of Lubiprostone in Chronic Idiopathic Constipation
por: Pennington, Becky, et al.
Publicado: (2018) -
A Randomized, Placebo-Controlled Trial of Lubiprostone for Opioid-Induced Constipation in Chronic Noncancer Pain
por: Jamal, M Mazen, et al.
Publicado: (2015) -
Effects of Lubiprostone, an Intestinal Secretagogue, on Electrolyte Homeostasis in Chronic Idiopathic and Opioid-induced Constipation
por: Rao, Satish S.C., et al.
Publicado: (2021)